Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Bexxar assigned priority review status by FDA

July 26, 1999

Klinge continues to focus on cytostatic/immunosuppressive carboxamides

July 21, 1999

AltaRex proposes increase in enrollment in OvaRex MAb trial

July 15, 1999

Zadaxin triple therapy shows promising results in preclinical model of colorectal cancer

July 14, 1999

Therion Biologics completes financing, accelerates therapeutic vaccine programs

July 9, 1999

Cell Genesys completes phase I/II GVAX trial and earns milestone payment

July 6, 1999

IL-4 fusion toxin effective in preclinical Kaposi's sarcoma models

July 2, 1999

Avax to launch M-Vax in Australia, forms joint venture for AC Vaccine

July 2, 1999

Transgene initiates phase I trial of malignant melanoma product

June 25, 1999

ImmunoGen receives second milestone payment for anticancer prodrug from SmithKline Beecham

June 22, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.